USP35

Summary

USP35 (ubiquitin specific peptidase 35, HGNC:20061) is a protein-coding gene on chromosome 11q14.1, encoding Ubiquitin carboxyl-terminal hydrolase 35 (Q9P2H5). Deubiquitinase that plays a role in different processes including cell cycle regulation, mitophagy or endoplasmic reticulum stress.

This gene encodes a member of the peptidase C19 family of ubiquitin-specific proteases. These deubiquitinating enzymes (DUBs) catalyze the removal of ubiquitin proteins from other proteins. The encoded protein associates with polarized mitochondria and has been shown to inhibit NF-kappa B activation and delay PARK2-mediated degradation of mitochondria. Expression of this gene is upregulated by the let-7a microRNA and reduced expression has been observed in human tumor tissues.

Source: NCBI Gene 57558 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 228 total
• Druggable target: yes
• MANE Select transcript: NM_020798

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20061
Approved symbol	USP35
Name	ubiquitin specific peptidase 35
Location	11q14.1
Locus type	gene with protein product
Status	Approved
Aliases	KIAA1372
Ensembl gene	ENSG00000118369
Ensembl biotype	protein_coding
OMIM	620959
Entrez	57558

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 1 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000526425, ENST00000528910, ENST00000529308, ENST00000530267, ENST00000530521, ENST00000530535, ENST00000530546, ENST00000869542, ENST00000913725, ENST00000951287

RefSeq mRNA: 1 — MANE Select: NM_020798 NM_020798

CCDS: CCDS41693

Canonical transcript exons

ENST00000529308 — 11 exons

Exon	Start	End
ENSE00001103559	78199595	78199724
ENSE00002149729	78196236	78196918
ENSE00002155034	78213646	78215232
ENSE00002196090	78188919	78189157
ENSE00003519568	78207530	78207623
ENSE00003528660	78200650	78200808
ENSE00003541855	78208857	78208963
ENSE00003594183	78200133	78200234
ENSE00003613392	78209448	78210744
ENSE00003629241	78205842	78206035
ENSE00003659910	78197936	78198068

Expression profiles

Bgee: expression breadth ubiquitous, 183 present calls, max score 94.12.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 4.1191 / max 53.4025, expressed in 1674 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
116015	3.7043	1588
116016	0.2724	111
116014	0.1425	41

Top tissues by expression

246 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
secondary oocyte	CL:0000655	94.12	gold quality
oocyte	CL:0000023	92.09	gold quality
pancreatic ductal cell	CL:0002079	91.92	silver quality
popliteal artery	UBERON:0002250	89.54	gold quality
tibial artery	UBERON:0007610	89.53	gold quality
right adrenal gland	UBERON:0001233	88.77	gold quality
right adrenal gland cortex	UBERON:0035827	88.71	gold quality
aorta	UBERON:0000947	88.13	gold quality
left adrenal gland cortex	UBERON:0035825	87.69	gold quality
left adrenal gland	UBERON:0001234	87.68	gold quality
ascending aorta	UBERON:0001496	86.90	gold quality
thoracic aorta	UBERON:0001515	86.61	gold quality
adrenal cortex	UBERON:0001235	86.24	gold quality
endothelial cell	CL:0000115	86.19	silver quality
adrenal gland	UBERON:0002369	86.07	gold quality
stromal cell of endometrium	CL:0002255	84.91	gold quality
right coronary artery	UBERON:0001625	84.88	gold quality
descending thoracic aorta	UBERON:0002345	84.86	gold quality
Brodmann (1909) area 23	UBERON:0013554	83.79	silver quality
adenohypophysis	UBERON:0002196	83.77	gold quality
left coronary artery	UBERON:0001626	83.72	gold quality
middle temporal gyrus	UBERON:0002771	83.49	silver quality
pituitary gland	UBERON:0000007	82.99	gold quality
coronary artery	UBERON:0001621	82.55	gold quality
right lobe of liver	UBERON:0001114	82.49	gold quality
right atrium auricular region	UBERON:0006631	82.21	gold quality
cortical plate	UBERON:0005343	81.82	gold quality
cardiac atrium	UBERON:0002081	81.15	gold quality
right frontal lobe	UBERON:0002810	80.99	gold quality
lower esophagus mucosa	UBERON:0035834	80.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.94

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

51 targeting USP35, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6772-5P	99.94	67.01	577
HSA-MIR-4525	99.94	64.38	675
HSA-MIR-5010-5P	99.94	64.11	705
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-539-5P	99.93	70.30	2855
HSA-MIR-5003-3P	99.85	69.29	2517
HSA-MIR-1197	99.70	67.75	1027
HSA-MIR-6762-3P	99.66	66.94	1188
HSA-MIR-561-3P	99.64	70.90	3647
HSA-MIR-1827	99.63	68.57	3265
HSA-MIR-6797-5P	99.61	66.55	2084
HSA-MIR-1249-5P	99.61	66.55	2049
HSA-MIR-4649-3P	99.56	66.90	1783
HSA-MIR-4708-3P	99.51	67.99	870
HSA-MIR-4519	99.48	66.10	859
HSA-MIR-6740-3P	99.48	68.49	1392
HSA-MIR-940	99.37	66.14	2064
HSA-MIR-6808-5P	99.31	66.23	2150
HSA-MIR-6893-5P	99.31	66.25	2119
HSA-MIR-3614-5P	99.30	65.25	837
HSA-MIR-3199	99.17	65.19	696
HSA-MIR-8052	99.17	65.01	719
HSA-MIR-7160-5P	99.11	67.17	2207
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-6846-5P	98.81	65.86	1121
HSA-MIR-6848-5P	98.81	65.49	1126

Literature-anchored findings (GeneRIF, showing 13)

• USP35 does not delay PARK2 recruitment (PMID:25915564)
• miR let-7a-regulated USP35 can inhibit NF-kappaB activation by deubiquitination and stabilization of ABIN-2 protein (PMID:26348204)
• findings suggest that USP35 regulates the stability and function of Aurora B by blocking APC(CDH1)-induced proteasomal degradation, thereby controlling mitotic progression (PMID:29449677)
• Two different USP35 isoforms that localise to different intracellular compartments and have distinct functions. (PMID:29685892)
• Genome-wide suppressor screen identifies USP35/USP38 as therapeutic candidates for ciliopathies. (PMID:31723061)
• Deubiquitinase USP35 restrains STING-mediated interferon signaling in ovarian cancer. (PMID:32678307)
• Deubiquitinase USP35 modulates ferroptosis in lung cancer via targeting ferroportin. (PMID:33931967)
• USP35, regulated by estrogen and AKT, promotes breast tumorigenesis by stabilizing and enhancing transcriptional activity of estrogen receptor alpha. (PMID:34131114)
• Regulation of survivin protein stability by USP35 is evolutionarily conserved. (PMID:34438346)
• USP35 mitigates endoplasmic reticulum stress-induced apoptosis by stabilizing RRBP1 in non-small cell lung cancer. (PMID:34618999)
• The deubiquitylating enzyme USP35 restricts regulated cell death to promote survival of renal clear cell carcinoma. (PMID:37173391)
• USP35 promotes hepatocellular carcinoma progression by protecting PKM2 from ubiquitination-mediated degradation. (PMID:37594129)
• Ubiquitin-specific Protease 35 Promotes Gastric Cancer Metastasis by Increasing the Stability of Snail1. (PMID:38250150)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Usp35	ENSMUSG00000035713
rattus_norvegicus	Usp35	ENSRNOG00000024961

Paralogs (71): USP2 (ENSG00000036672), USP28 (ENSG00000048028), USP36 (ENSG00000055483), USP13 (ENSG00000058056), USP33 (ENSG00000077254), USP40 (ENSG00000085982), USP48 (ENSG00000090686), USP14 (ENSG00000101557), USP11 (ENSG00000102226), USP10 (ENSG00000103194), USP31 (ENSG00000103404), USP42 (ENSG00000106346), USP5 (ENSG00000111667), USP4 (ENSG00000114316), USP9Y (ENSG00000114374), USP34 (ENSG00000115464), USP45 (ENSG00000123552), USP22 (ENSG00000124422), USP9X (ENSG00000124486), USP6 (ENSG00000129204), USP29 (ENSG00000131864), USP26 (ENSG00000134588), USP30 (ENSG00000135093), USP15 (ENSG00000135655), USP37 (ENSG00000135913), USP44 (ENSG00000136014), USP20 (ENSG00000136878), USP8 (ENSG00000138592), USP3 (ENSG00000140455), USP21 (ENSG00000143258), USP43 (ENSG00000154914), USP25 (ENSG00000155313), USP16 (ENSG00000156256), USP24 (ENSG00000162402), USP1 (ENSG00000162607), USP49 (ENSG00000164663), USP38 (ENSG00000170185), USP50 (ENSG00000170236), USP47 (ENSG00000170242), USP32 (ENSG00000170832)

Protein

Protein identifiers

Ubiquitin carboxyl-terminal hydrolase 35 — Q9P2H5 (reviewed: Q9P2H5)

Alternative names: Deubiquitinating enzyme 35, Ubiquitin thioesterase 35, Ubiquitin-specific-processing protease 35

All UniProt accessions (4): Q9P2H5, E9PK78, E9PRM2, H0YEP1

UniProt curated annotations — full annotation on UniProt →

Function. Deubiquitinase that plays a role in different processes including cell cycle regulation, mitophagy or endoplasmic reticulum stress. Inhibits TNFalpha-induced NF-kappa-B activation through stabilizing TNIP2 protein via deubiquitination. Plays an essential role during mitosis by deubiquitinating and thereby regulating the levels of Aurora B/AURKB protein. In addition, regulates the protein levels of other key component of the chromosomal passenger complex (CPC) such as survivin/BIRC5 or Borealin/CDCA8 by enhancing their stability. Regulates the degradation of mitochondria through the process of autophagy termed mitophagy.

Subunit / interactions. Homodimer (via C-terminal region). Interacts with HSP90AA1.

Subcellular location. Cytoplasm. Mitochondrion.

Tissue specificity. Expressed in testis, pancreas and skeletal muscle.

Post-translational modifications. Ubiquitinated by CHIP/STUB1 in an HSP90-dependent manner; leading to proteasomal degradation. This ubiquitination can be reversed through auto-deubiquitinating activity.

Induction. By FOXM1 transcription factor.

Similarity. Belongs to the peptidase C19 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9P2H5-1	1	yes
Q9P2H5-2	2

RefSeq proteins (1): NP_065849* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001394	Peptidase_C19_UCH	Domain
IPR016024	ARM-type_fold	Homologous_superfamily
IPR018200	USP_CS	Conserved_site
IPR028889	USP	Domain
IPR038765	Papain-like_cys_pep_sf	Homologous_superfamily
IPR049407	Usp38-like_N	Domain
IPR050164	Peptidase_C19	Family

Pfam: PF00443, PF21246

UniProt features (49 total): strand 17, helix 10, compositionally biased region 5, region of interest 3, turn 3, active site 2, mutagenesis site 2, sequence conflict 2, chain 1, domain 1, modified residue 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

4 structures.

PDB	Method	Resolution (Å)
9F6G	X-RAY DIFFRACTION	1.5
5TXK	X-RAY DIFFRACTION	1.84
7Q44	X-RAY DIFFRACTION	2.2
9F19	X-RAY DIFFRACTION	2.75

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9P2H5-F1	76.56	0.46

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (2): 450 (nucleophile); 862 (proton acceptor)

Post-translational modifications (1): 613

Mutagenesis-validated functional residues (2):

Position	Phenotype
450	complete loss of catalytic activity.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (3): proteolysis (GO:0006508), protein deubiquitination (GO:0016579), regulation of protein stability (GO:0031647)

GO Molecular Function (4): cysteine-type deubiquitinase activity (GO:0004843), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787)

GO Cellular Component (4): nucleus (GO:0005634), mitochondrion (GO:0005739), cytosol (GO:0005829), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular membrane-bounded organelle	2
cytoplasm	2
cellular anatomical structure	2
protein metabolic process	1
cysteine-type deubiquitinase activity	1
protein modification by small protein removal	1
regulation of biological quality	1
cysteine-type peptidase activity	1
deubiquitinase activity	1
hydrolase activity	1
catalytic activity, acting on a protein	1
peptidase activity	1
catalytic activity	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

948 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
USP35	USP30	Q70CQ3	761
USP35	ZUP1	Q96AP4	565
USP35	USP13	Q92995	518
USP35	USP39	Q53GS9	517
USP35	USP14	P54578	494
USP35	USP53	Q70EK8	457
USP35	USP54	Q70EL1	454
USP35	MARCHF5	Q9NX47	448
USP35	MAVS	Q7Z434	426
USP35	PAN2	Q504Q3	419
USP35	OTUD6A	Q7L8S5	413
USP35	PINK1	Q9BXM7	413
USP35	KCTD21	Q4G0X4	408
USP35	FKBP8	Q14318	406
USP35	USP11	P51784	404

IntAct

7 interactions, top by confidence:

A	B	Type	Score
TRIM63	USP35	psi-mi:“MI:0915”(physical association)	0.400
TRIM55	USP35	psi-mi:“MI:0915”(physical association)	0.400
TRIM54	USP35	psi-mi:“MI:0915”(physical association)	0.400
ZNF20	ZNF316	psi-mi:“MI:0914”(association)	0.350
ZNF736	PPM1G	psi-mi:“MI:0914”(association)	0.350
FHIP1B	MED19	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (81): USP35 (Affinity Capture-MS), USP35 (Affinity Capture-Western), TMEM173 (Affinity Capture-Western), TNIP2 (Affinity Capture-MS), USP35 (Affinity Capture-Western), USP35 (Reconstituted Complex), AURKB (Affinity Capture-Western), USP35 (Affinity Capture-Western), USP35 (Negative Genetic), MAVS (Affinity Capture-Western), USP35 (Two-hybrid), TMEM173 (Biochemical Activity), USP35 (Affinity Capture-Western), TMEM173 (Affinity Capture-Western), USP35 (Reconstituted Complex)

ESM2 similar proteins: A0JM59, A2BGT0, A5PJS6, A5PMR2, A5PN09, A6QNM7, A7Z056, B1AY15, B1WBD7, D2HBJ8, E1C213, E7F6T8, E9QG68, O88974, P52479, Q0V9G5, Q14694, Q15047, Q1RMU2, Q28CN3, Q2KJ09, Q2NL57, Q3KR59, Q5R5Z6, Q5RED8, Q5REG5, Q5XGZ2, Q5ZJN4, Q66H62, Q6NTR6, Q6P549, Q70CQ3, Q70CQ4, Q70EK9, Q7ZUM8, Q7ZXR7, Q80TQ2, Q8BW70, Q8C0R0, Q8C2S0

Diamond homologs: A0A0R4IB93, A0JM59, A1CIL1, A1CW53, A2XDG4, A3AF13, A5PN09, A6QNM7, A7Z056, B1WBD7, B2GUZ1, B8NSV5, D3ZJ96, F6Z5C0, O22207, O60079, O94966, Q0CT11, Q0E2F9, Q0VA64, Q13107, Q2HJE4, Q2UUG8, Q3UJD6, Q3V0C5, Q4VSI4, Q5I043, Q5R5Z6, Q5RCD3, Q5ZM45, Q60MK8, Q6A4J8, Q6J1Y9, Q6PAW2, Q6U7I1, Q6ZQ93, Q70CQ2, Q76LT8, Q7JKC3, Q84WU2

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

228 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	197
Likely benign	7
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

2223 predictions. Top by Δscore:

Variant	Effect	Δscore
11:78196235:GC:G	acceptor_gain	1.0000
11:78197934:A:AG	acceptor_gain	1.0000
11:78197934:AGAG:A	acceptor_gain	1.0000
11:78197935:G:GG	acceptor_gain	1.0000
11:78197935:GA:G	acceptor_gain	1.0000
11:78197935:GAGG:G	acceptor_gain	1.0000
11:78197935:GAGGA:G	acceptor_gain	1.0000
11:78198064:AGCAG:A	donor_loss	1.0000
11:78198065:GCAGG:G	donor_loss	1.0000
11:78198066:CAGGT:C	donor_loss	1.0000
11:78198067:AGGT:A	donor_loss	1.0000
11:78198068:GGTGG:G	donor_loss	1.0000
11:78198070:T:G	donor_loss	1.0000
11:78198082:GC:G	donor_gain	1.0000
11:78199621:T:TA	acceptor_gain	1.0000
11:78199721:GAAG:G	donor_gain	1.0000
11:78199722:AAG:A	donor_loss	1.0000
11:78199723:AGG:A	donor_loss	1.0000
11:78199725:GTT:G	donor_loss	1.0000
11:78199726:T:A	donor_loss	1.0000
11:78200648:A:AG	acceptor_gain	1.0000
11:78200649:G:GG	acceptor_gain	1.0000
11:78200671:AT:A	acceptor_gain	1.0000
11:78200672:T:TA	acceptor_gain	1.0000
11:78200684:T:TA	acceptor_gain	1.0000
11:78200810:T:G	donor_loss	1.0000
11:78205841:G:GT	acceptor_gain	1.0000
11:78205994:C:G	donor_gain	1.0000
11:78206016:GCCT:G	donor_gain	1.0000
11:78206028:GCGTC:G	donor_gain	1.0000

AlphaMissense

6587 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
11:78196256:T:C	I4T	1.000
11:78199605:T:A	W273R	1.000
11:78199605:T:C	W273R	1.000
11:78199614:T:A	W276R	1.000
11:78199614:T:C	W276R	1.000
11:78199641:T:A	W285R	1.000
11:78199641:T:C	W285R	1.000
11:78205896:T:A	W418R	1.000
11:78205896:T:C	W418R	1.000
11:78205968:G:C	G442R	1.000
11:78205969:G:A	G442D	1.000
11:78205972:T:C	L443P	1.000
11:78205979:C:A	N445K	1.000
11:78205979:C:G	N445K	1.000
11:78205992:T:C	C450R	1.000
11:78205993:G:A	C450Y	1.000
11:78205994:C:G	C450W	1.000
11:78206004:A:C	S454R	1.000
11:78206006:C:A	S454R	1.000
11:78206006:C:G	S454R	1.000
11:78208930:A:C	D520A	1.000
11:78208930:A:T	D520V	1.000
11:78208945:T:C	L525P	1.000
11:78208954:T:C	L528P	1.000
11:78196256:T:A	I4N	0.999
11:78196256:T:G	I4S	0.999
11:78196259:T:C	L5S	0.999
11:78196299:G:C	K18N	0.999
11:78196299:G:T	K18N	0.999
11:78198017:T:C	L252P	0.999

dbSNP variants (sampled 300 via entrez): RS1000063506 (11:78206320 G>C,T), RS1000116380 (11:78202543 A>G), RS1000167572 (11:78229964 G>A,T), RS1000276307 (11:78214864 G>A,C), RS1000309332 (11:78229764 C>A), RS1000316642 (11:78197175 G>T), RS1000338851 (11:78187227 CTT>C), RS1000342286 (11:78230005 A>G,T), RS1000386223 (11:78218666 C>G), RS1000455997 (11:78203680 G>A), RS1000474170 (11:78208775 G>C), RS1000526375 (11:78235217 A>C,G), RS1000613889 (11:78198278 A>G), RS1000628604 (11:78235146 G>C), RS1000680777 (11:78198787 A>C,G)

Disease associations

OMIM: gene MIM:620959 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST003246_2	Testicular germ cell tumor	1.000000e-10
GCST007277_15	Tourette syndrome	5.000000e-06
GCST007656_10	Chronic obstructive pulmonary disease or resting heart rate (pleiotropy)	4.000000e-12
GCST90013405_23	Liver enzyme levels (alanine transaminase)	3.000000e-10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL4630862 (SINGLE PROTEIN)

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	decreases methylation, increases expression	2
Valproic Acid	affects expression, decreases methylation	2
aristolochic acid I	increases expression	1
FR900359	decreases phosphorylation	1
bisphenol A	affects cotreatment, decreases methylation	1
arsenite	affects binding, decreases reaction	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
jinfukang	affects cotreatment, increases expression	1
Sunitinib	decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Leflunomide	decreases expression	1
Acetaminophen	decreases expression	1
Air Pollutants	affects response to substance, increases abundance	1
Azathioprine	increases expression	1
Cisplatin	affects cotreatment, increases expression	1
Nitrogen Oxides	increases abundance, affects response to substance	1
Quercetin	increases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	increases expression	1
Urethane	affects expression	1
Cyclosporine	increases expression	1
Copper Sulfate	increases expression	1
Particulate Matter	affects response to substance, increases abundance	1

ChEMBL screening assays

3 unique, capped per target: 3 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL4605987	Binding	Inhibition of USP35 (unknown origin)	Discovery of Potent, Selective, and Orally Bioavailable Inhibitors of USP7 with In Vivo Antitumor Activity. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TW93	HAP1 USP35 (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.